Company profile
Adlai Nortye Ltd.
NASDAQ: ANL · Healthcare · Biotechnology
PublicHQ Grand Cayman, CIK 0001944552Reports USD
#1 of 1,418 Healthcare companies by revenue
EA Score
——FH —DQ —GM —SS 50
v0.1 · 5/100 weight · pillars only
↑ market scale, workforce scale · ↓ Piotroski F, filing timeliness
Methodology →Revenue TTM
$19.7M
Rev growth YoY (TTM)
+203.2%
Net income (FY)
-$51.9M
Employees
109
as of 2026-07-19
Market cap
$602.5M
as of 2026-07-19
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Net income-$51.9M-$51.9M2024
Total assets$71.3M$71.3M2024
Liabilities$45.8M$45.8M2024
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Adlai Nortye Ltd.’s financial profile?
Adlai Nortye Ltd. earned -$51.9M in FY2024 net income.
Peers · Healthcare
Cybin Inc. Common Stock——Jade Biosciences, Inc.——Tectonic Therapeutic, Inc.——GMR Solutions Inc.——Odyssey Therapeutics, Inc.——Zura Bio Limited——Key facts
CEOYang Lu
SectorHealthcare
IndustryBiotechnology
HeadquartersGrand Cayman, null
ExchangeNASDAQ: ANL
Employees109
IPO date2023-09-29
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.